Brain Oligometastasis in NSCLC (OligoLung)

January 28, 2026 updated by: University Hospital, Bordeaux

Management of Patients With Brain-onset Oligometastatic Non-small-cell Lung Cancer (NSCLC)

75-80% of NSCLC are diagnosed at the metastatic stage. Among the most frequent sites are brain metastases. The management of patients with exclusive limited brain involvement is not standardized. The question is therefore which therapeutic strategy is optimal in such disease presentation. We will analyze the impact of different therapeutic strategies on patients treated at Bordeaux University Hospital and the Bergonié Institute

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Detailed Description

75-80% of NSCLC are diagnosed at the metastatic stage. Among the most frequent sites are brain metastases. The management of patients with exclusive limited brain involvement is not standardized. The question is therefore which therapeutic strategy is optimal in terms of disease control: local treatment of the main tumor and brain versus systemic treatment with chemotherapy and immunotherapy. We will analyze the impact of these 2 strategies on patients treated at Bordeaux University Hospital and the Bergonié Institute.

Study Type

Observational

Enrollment (Actual)

46

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
      • Bordeaux, France
        • CHU de Bordeaux

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

N/A

Sampling Method

Non-Probability Sample

Study Population

Patient with NSCLC treated at CHU Bordeaux and Bergonié Institute

Description

Inclusion Criteria:

  • Consecutive patients managed at Bordeaux University Hospital
  • Non-small-cell lung cancer
  • Oligometastatic brain cancer (fewer than 5 lesions at diagnosis)
  • Patient over 18 years old

Exclusion Criteria:

  • Oncogenic addiction EGFR, ALK, ROS1
  • Patient with concomitant cancer
  • Patient with prior treatment for lung cancer in the year preceding diagnosis at metastatic stage

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Local treatments
Local multimodal treatments (thoracic surgery/radiotherapy + brain surgery/radiotherapy)
Other: Standard treatments / multiple strategies
Standard treatments / multiple strategies
Systemic treatment
Chemoimmunotherapy combination
Other: Standard treatments / multiple strategies
Standard treatments / multiple strategies

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Progression free survival (PFS)
Time Frame: Once, at progression or death from any cause
Time from random assignment in a clinical trial to disease progression or death from any cause
Once, at progression or death from any cause

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
PFS from the date of the next treatment to disease progression or death from any cause (PFS2)
Time Frame: Once, at progression or death from any cause
PFS from the date of the next treatment to disease progression or death from any cause
Once, at progression or death from any cause
Overall survival (OS)
Time Frame: Once, death from any cause or lost of follow-up
Time from either the date of diagnosis or the start of treatment for a disease, such as cancer, that patients diagnosed with the disease are still alive
Once, death from any cause or lost of follow-up

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Hospital, Bordeaux

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2025

Primary Completion (Estimated)

March 1, 2026

Study Completion (Estimated)

March 1, 2026

Study Registration Dates

First Submitted

January 28, 2026

First Submitted That Met QC Criteria

January 28, 2026

First Posted (Actual)

February 5, 2026

Study Record Updates

Last Update Posted (Actual)

February 5, 2026

Last Update Submitted That Met QC Criteria

January 28, 2026

Last Verified

January 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CHUBX 2025/058

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Non-small Cell Lung Cancer

Clinical Trials on Standard treatments / multiple strategies

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Colombia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe